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Improving the Model of Care
Pregnant Women With Opioid Use Disorder
• 52% of maternal deaths in Alaska in the past 6 years were related to 
alcohol abuse or substance use disorders
• Overall, there is a steady increase in opioid related deaths
• Infants identified with Neonatal Abstinence Syndrome has increase 
from 4.4 per 1000 live birth to 23.2 per 1000 live births over the last 10 
years
• In 2017 PAMC experienced a significant increase in pregnant women 
presenting actively using opioids. 138 women or about 5% of the 
patient population tested positive for opioids
• In review of these cases, it was clear we had an inconsistent way we 
identified, treated, and supported these women
• A review of the literature identified protocols for women prenatally and 
in the postpartum period
• There was a lack of protocols for women presenting in labor with 
opioid use
• The team recognized that the care of these patients did not align with the 
Providence St. Joseph Health’s mission and core values
• The team set out to create a list of Guiding Principles that would shape 
the Clinical Pathway
• At the center of this work was embracing the principles of Trauma 
Informed Care 
• The team encouraged collaboration amongst caregivers and 
departments
• This process brought forth open and frank conversations with patients 
and caregivers and became the basis of our culture change.
Our Problem
• During case review and interviews with staff and providers, it became 
clear that the care of these women was highly variable
• A large number of patients who were tested for opioids because of 
demonstrating signs of withdrawal had their positive drug screen 
dismissed by providers
• Examples of treatment included:
• Denial of opioid replacement or medication assisted treatment
• Room searches or belongings confiscation
• Room sitters
• Limited visitors
• Prevented from leaving the unit




• The disease of addiction is a chronic medical condition that can be 
managed through compassionate respectful clinical interventions.  
• Patients that have opioid use disorder will be treated with evidence-
based strategies for withdrawal prevention, management of withdrawal 
symptoms, and pain management.  
• Caregivers will learn about the disease of addiction and develop 
communication tools that allow them to partner with patients around the 
disease. 
• It is possible and necessary to build a positive relationship between 
caregivers and patients that suffer from substance use disorders.  
Patients can learn to be curious about the disease and talk with their 
providers around their readiness for change and goals for health.
• Caregivers recognize that moral judgments do not produce positive 
health outcomes.
• Caregivers will use appropriate clinical terms that describe behaviors and 
symptoms of disease to decrease the stigma associated with addiction.
• Caregivers will partner with patients and visitors to discuss the safety 
issues that present around substance use.   
• Trauma informed care will guide all practice. 
• Patients will not routinely have their room searched or be placed on 
continuous visual observation, unless it is determined they are at 
imminent risk of harm to themselves. Patients are autonomous and 
ultimately in charge of their own health.
• Visitors and designated care providers will not be restricted as long as 
they follow the visitation policy.
• All patients that are suffering from the disease of addiction deserve 
effective medical care.  When patients suffer from an addiction they use 
substances to manage their addiction.  We will not criminalize the use of 
substances while patients are in medical care.
• Any decisions to report use or possession are made by the entire care 
team, in conjunction with Security and Risk Management.
• The focus of care is on reducing the negative consequences and high 
risk behaviors of substance use (harm reduction); it neither condones nor 
condemns any behavior.
• In situations where the medical team and/or the family feel it is in the best 
interest of the family and child, breastfeeding is encouraged and 
supported.
• Opioid replacement will be the standard of care and implemented with 
current evidence-based standards including multi-modal pain control.
• Care plans will be created by a multidisciplinary team including mental 
health, chemical dependency specialists, social work, and pain 
management.
Guiding Principles
• Created to guide care and provide consistency
• Begins with the Guiding Principles
• Meets patients where they are
• Identifies a list of interventions to be initiated on admission
• Divided into three phases of care (antepartum, intrapartum, 
postpartum)
• Separated by system (cardiac, respiratory, digestive…..)
• Helps the caregiver recognize signs of withdrawal (COWS scoring)
• Includes evidence based Medication Assisted Treatment (MAT) 
guidelines
• The basis of the work:
• Identify signs of withdrawal
• Replace opioids
• Refer to an outpatient replacement program
• Pathway contains suggestive scripting
• Incudes a change in vocabulary
• Scripting was vetted with patients in treatment
• Begins with a conversation initiated by nurses:
• “What does withdrawal look like to you”
• “I want to partner with you to keep you from experiencing 
withdrawal symptoms
• Creates a pathway to transition women to MAT while in the hospital 
and immediately refer them to Providence Breakthrough for additional 
treatment and support
Pathway Example
• Instead of avoiding caring for this patient population, the nurses became 
excited
• Patient’s reported increase in trust, compassion, and acceptance
• Women were successfully transitioned to MAT
• Patients presenting in labor on MAT had better pain management plans
Clinical Pathway
• Maternity Nurses, Leaders and Care Providers
• Behavioral Health Leaders, Nurses, Therapists, and Psychiatrists
• Pain Service/ Anesthesia Physicians
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Admission 
 Screen all women privately. Patients must feel safe and have a sense of trust.  
 Assess for Risk Factors: 
 Little or no prenatal care (High risk) 
 Inappropriate behaviors (High risk) 
 Physical signs of opioid use or withdrawal (High risk) 
 Smell of alcohol or illicit substances (High risk) 
 Recent history or use (High risk) 
 History of physical abuse or neglect 
 Intimate partner violence 
 Mental illness 
 Previous child with fetal alcohol syndrome 
 History of repeat spontaneous abortions 
 Observe for signs of opioid intoxication or withdrawal (Attachment A) 
 Send urine drug screen to confirm use of opioids 
 Initiate COWS Scoring (Attachment B) 
 Contact the Maternity Social worker during weekdays and during the daytime hours and/or On-Call Social Worker during nights and weekends. Inform them of the 
need for a social work consult for a patient with Opioid Use Disorder. Also place the consult in EPIC. 
 Social work will complete a psychosocial assessment and determine motivation to change. 
 Social work will provide therapeutic support and resources to the patient as determined via their assessment. 
 Social work will initiate conversations about OCS involvement  
 If admitted for reasons other than opioid use and the patient desires Medication Assisted Treatment (MAT), social work will partner with the attending physician and 
Breakthrough Clinic to determine transition of care from inpatient to outpatient community. 
 Initiate consults to Chemical Dependency Clinician 
 If admitted for other reason than opioid use and desires medication assisted treatment (MAT), initiate consult to Breakthrough Clinic  
 When medically appropriate, attending physician to initiate medication assisted treatment.  
 Initiate No Prenatal Care orders if applicable 
 Assess for smoking and desire for nicotine replacement; replace as appropriate with combined Nicotine Replacement Therapy (NRT) [patch daily and 
lozenge/gum/inhaler prn] 
 
 Placenta abruption 
 Preterm labor 
 Intrauterine growth restriction 
 Previous unexplained fetal demise 
 Hypertensive episodes 
 History of stroke or heart attack 
 Severe mood swings 
 
 Antepartum Intrapartum Postpartum 
Pain 
Goals: 
• Attain adequate pain 
control 
• Achieve pain control 
with lowest possible 
opioid dose 





Patients without current opioid 
replacement 
 Score q4hour with COWS  
o For COWS 5 – 12  give oxycodone 
5 mg  OR hydromorphone 2 mg po 
o For COWS 13 – 24 give oxycodone 
10 mg OR hydromorphone 4 mg 
po 
o For COWS 25 – 36 give oxycodone 
15 mg OR hydromorphone 6 mg 
po  
o For COWS > 36 give oxycodone 20 
mg OR hydromorphone 8 mg po  
o For break through pain 
management: 
 Hydromorphone 0.4-
0.8 mg IV q2 hours 
prn  
For those who are anticipated to have a 
long pre-delivery length of stay, initiate 
discussions regarding Medication Assisted 
Treatment (MAT)  
• If patient desires MAT, and it is 
medically appropriate, perform 
buprenorphine induction (per 
attachment) 
• In pregnancy, buprenorphine-only 
formulations (without naloxone) 
should be utilized. 
• Once buprenorphine initiated, follow 
“patients on buprenorphine” section 
for intrapartum and post-partum care 
• Methadone MAT is an alternative if 
this is desired by the patient. 
Methadone should be titrated to 
target not only withdrawal symptoms, 
but cravings. Split dosing (bid) 
recommended in pregnancy. 
Patients without current opioid replacement 
 Score q4hour with COWS  
o For COWS 5 – 12  give oxycodone 5 mg  OR 
hydromorphone 2 mg po 
o For COWS 13 – 24 give oxycodone 10 mg OR 
hydromorphone 4 mg po 
o For COWS 25 – 36 give oxycodone 15 mg OR 
hydromorphone 6 mg po  
o For COWS > 36 give oxycodone 20 mg OR 
hydromorphone 8 mg po  
o For break through pain management: 
 Hydromorphone 0.4-0.8 mg IV q2 
hours prn  
When a patient is in labor with impending delivery, it is 
not an appropriate time to initiate MAT, this 
conversation can continue after delivery.  
Patients without current opioid 
replacement 
• Begin/resume discussion regarding 
MAT.  
• Once acute pain managed, as below, 
if patient desires MAT, perform 
buprenorphine induction 
Attachment D).   
• Methadone MAT is an alternative if 
this is desired by the patient. 
Methadone should be titrated to 
target not only withdrawal 
symptoms, but cravings. 
Pain management following vaginal 
delivery: 
• Continue COWS and prn 
oxycodone/hydromorphone for 
withdrawal symptoms 
• Ibuprofen 600 mg po 4h prn mild to 
moderate pain 
• Tylenol 650 mg po q6h prn moderate 
to severe pain 
Pain management following c-section 
• Consider “TAP”- Transversus 
abdominis plane block. Administered 
by Anesthesiologist. Consent 
obtained prior to procedure. 
• Continue COWS and prn 
oxycodone/hydromorphone for 
withdrawal symptoms 
• Acetaminophen 650 mg po q6h  
• Ketorolac  30 mg IV q6 hr for 24 
hours, followed by: 
• Ibuprofen 600 mg po q6h  
• Consider prn IV Opioids if 
breakthrough pain persists 
Lessons Learned
• Collaboration takes time. This project took over a year to develop
• You can never have enough stakeholders
• Not every patient will follow the guideline
• You can change culture…a bit at a time
• The disease of addiction allows for failure
• Opioid Use Disorder is not going away
• Connection and compassion are magical
